Immune System Disorders | NYU Langone Health
NYU Langone doctors specialize in treating immune and autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosis, and more.
Immunotherapy & Targeted Therapies for Colorectal Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may prescribe immunotherapy or targeted therapies to treat colorectal cancer.
Immunotherapy for Glioma & Astrocytoma | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may use immunotherapy to prevent glioma or astrocytoma tumors from growing or spreading.
Immunotherapy for Myasthenia Gravis | NYU Langone Health
NYU Langone specialists may administer a protein called immunoglobulin to treat severe myasthenia gravis.
Immunotherapy for Vasculitis | NYU Langone Health
Langone doctors may prescribe intravenous immunoglobulin therapy for people with more serious forms of vasculitis.
Impact of time restricted feeding in obese subjects undergoing a low-calorie diet
The impact of circadian rhythms appear to impact various biologic mechanisms including sleep, nutrition, and physical activity. We wish to understand the impact of timing of food consumption and how it may affect weight loss. Participants in the study will be undergoing a low calorie diet, and we will attempt to vary the times at which participants will eat. We will examine differences in rates of weight loss over the course of two, four and eight weeks. This will be an initial pilot study in an attempt to see if there is more effective weight loss with time restricted feeding.
Impact of Weight Loss in Patients with Hypertrophic Cardiomyopathy
This is an observational imaging study to evaluate the cardiac effects of weight loss in obese patients with a BMI >=30 with a confirmed diagnosis of hypertrophic cardiomyopathy. The sample size will be 120 patients. Based on the clinical evaluation of the NYU Langone Health Weight Management Program and on patient preference, patients will be offered either bariatric surgery or a diet and exercise regimen. Patient management before, during, and after weight loss intervention(s), including subsequent follow-up, will be in accordance to standard of care. Patients will have echocardiographic and quantitative radiographic imaging either by Cardiac MRI or ECG-Synchronized cardiac CT angiogram of the chest no more than 3 months before and again 18 months after their patient-chosen weight loss program. MRI is the preferred method of radiographic imaging while CT will be reserved only for patients who have a pacemaker or implanted cardiac defibrillator. Patients who do not complete their chosen weight loss program or those who do not lose weight by the End of Study visit will still undergo final research imaging procedures for comparison analysis.
Impella -Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial
The primary objective of the PROTECT IV Trial is to demonstrate the superiority of percutaneous coronary intervention (PCI) performed with Impella mechanical circulatory support (MCS; Impella CP®, Impella CP® with SmartAssist® or Impella 2.5® devices) compared with PCI without Impella in high-risk patients with reduced left ventricular ejection fraction undergoing percutaneous intervention of complex coronary artery disease (CAD). The principal hypothesis is that by providing effective hemodynamic support in high-risk patients with reduced left ventricular systolicfunction and complex CAD undergoing high-risk PCI, Impella mechanical circulatory support will facilitate a safer procedure with higher rates of optimal and complete revascularization, which will lead to improved event-free survival, quality of life (QoL) and functional outcomes at 3-year followup.
Implantable Cardioverter Defibrillator for Ventricular Arrhythmias | NYU Langone Health
NYU Langone doctors use implanted cardioverter defibrillators to manage the symptoms of ventricular arrhythmias.
IMPROVING MUSIC PERCEPTION IN COCHLEAR IMPLANTS
In this multi-site across-subject study, participants will be evaluated with custom written software to test pitch discrimination, the ability to perceive changes in melodic intervals, and pitch sound quality. Testing will occur in a soundbooth or quiet environment with the stimuli being presented through a direct audio input (DAI) cable connected to the cochlear implant and an insert earphone to the AH ear. No changes will be made to a cochlear implant user’s device or settings. Individuals will listen to various tones, complex sounds or melodies and make judgements based on what they perceive. These judgements will be recorded using a custom interface on a touch screen computer, or with a computer mouse.
